DGAP-News: Epigenomics AG / Key word(s): Capital Increase27.04.2021 / 17:40 The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA. Press release Epigenomics AG decides to increase share capital through rights […]
Category: Press Releases
27. April 2021
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Read more
20. April 2021
Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024
DGAP-News: Epigenomics AG / Key word(s): Bond/Miscellaneous20.04.2021 / 15:39 The issuer is solely responsible for the content of this announcement. Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024 Berlin (Germany) and San Diego (U.S.A.), April 20, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the […]
06. April 2021
Study reported in BMC Gastroenterology shows significantly better performance characteristics of Epigenomics’ liver cancer panel compared to the current standard of care for the early detection of HCC
DGAP-News: Epigenomics AG / Key word(s): Study results/Study06.04.2021 / 07:59 The issuer is solely responsible for the content of this announcement. Study reported in BMC Gastroenterology demonstrates significantly better performance characteristics of Epigenomics’ liver cancer panel compared to the current standard of care for the early detection of hepatocellular carcinoma (HCC) in patients with liver […]
25. March 2021
Epigenomics AG Reports Financial Results for Fiscal Year 2020
DGAP-News: Epigenomics AG / Key word(s): Annual Report/Annual Results25.03.2021 / 11:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for Fiscal Year 2020 Berlin (Germany) and San Diego, CA (U.S.A.), March 25, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today reported financial results (according […]
27. January 2021
Epigenomics AG: Dr. Garces transitions to Company Advisor
DGAP-News: Epigenomics AG / Key word(s): Personnel27.01.2021 / 08:37 The issuer is solely responsible for the content of this announcement. Epigenomics AG: Dr. Garces transitions to Company Advisor Berlin (Germany) and San Diego, CA (USA), January 27, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that Dr. Jorge Garces, President […]
21. January 2021
Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/Scientific publication21.01.2021 / 10:02 The issuer is solely responsible for the content of this announcement. Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening Company evaluating all options to challenge CMS’ decision to non-cover the Epi proColon test New […]